Legend Biotech (LEGN) Payables (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Payables data on file, last reported at $74.3 million in Q1 2026.

• Quarterly Payables rose 27.79% year-over-year to $74.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.3 million (up 27.79% YoY) and the FY2025 annual result came in at $83.0 million, up 115.03% from the prior year.
• Payables eased to $74.3 million in Q1 2026, from $83.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $102.5 million in Q3 2025 to a low of $17.2 million in Q3 2023.
• A 5-year average of $45.9 million and a median of $38.6 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables jumped 201205.83% — and 2023, when it retreated 6.8%.
• Tracing LEGN's Payables over 5 years: stood at $32.9 million in 2022, then retreated by 6.8% to $30.7 million in 2023, then advanced by 25.92% to $38.6 million in 2024, then soared by 115.03% to $83.0 million in 2025, then slipped by 10.48% to $74.3 million in 2026.
• The last three Payables figures came in at $74.3 million (Q1 2026), $83.0 million (Q4 2025), and $102.5 million (Q3 2025), per Business Quant data.